Skip to content

Prepaid expenses at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Arrowhead Research logo
Arrowhead ResearchARWR
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's prepaid expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's prepaid expenses?
Acadia Pharmaceuticals (ACAD) reported prepaid expenses of $64.6M in Q1 2026.
How has Acadia Pharmaceuticals's prepaid expenses changed year-over-year?
Acadia Pharmaceuticals's prepaid expenses increased by 22.6% year-over-year, from $52.7M to $64.6M.
What is the long-term trend for Acadia Pharmaceuticals's prepaid expenses?
Over 5 years (2020 to 2025), Acadia Pharmaceuticals's prepaid expenses has grown at a 18.3% compound annual growth rate (CAGR), from $25.69M to $59.53M.